Dr. Lindsey Rolfe
BSc, MB ChB, MRCP, FFPM
Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance and Chief Medical Officer
Dr. Lindsey Rolfe joined Clovis in April 2010 and has served as the Executive Vice President of Clinical and Pre-clinical Development and Pharmacovigilance and Chief Medical Officer since 2015. Dr. Rolfe joined Clovis in April 2010 and served as Senior Vice President of Clinical Development until her promotion. Dr. Rolfe has 20 years of drug development experience and previously served in senior oncology development roles at Celgene Corporation, Pharmion Corporation, Cambridge Antibody Technology, UCB Inc. and Celltech Group plc. Dr. Rolfe also serves on the board of directors for Atreca, Inc. (NASDAQ: BCELL). Dr. Rolfe qualified in medicine at the University of Edinburgh. She undertook post graduate medical training in London, UK and obtained her post-graduate internal medicine qualification as a Member of the Royal College of Physicians (MRCP). She has specialist accreditation in Pharmaceutical Medicine from the UK General Medical Council and is a Fellow of the Faculty of Pharmaceutical Medicine.